Propranolol vs Retatrutide
FDA Approved vs Extensively Studied
monitor Mechanism-based · 55% Both Propranolol and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Propranolol Retatrutide
Weight 259.34 Da 4,731.33 Da
Half-life ~4-5 hours ~6 days
Chain — 39 amino acids
Type Aryloxypropanolamine derivative (C16H21NO2) Triple GLP-1/GIP/glucagon agonist
Key Benefits
Propranolol
01 Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
02 Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
03 Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
04 Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
05 Extensive clinical safety data spanning over 50 years of use
06 Inexpensive and widely available as a generic medication
07 Does not cause dependence or withdrawal symptoms typical of benzodiazepines
08 Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Propranolol
10-80 mg/day / 1-3 times daily (or as needed)
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Propranolol
Fatigue and reduced exercise tolerance, particularly during the first week of use
Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation
Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic
Dizziness or lightheadedness, especially when standing quickly
Gastrointestinal discomfort (nausea, diarrhea, constipation)
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Asthma or severe reactive airway disease (non-selective beta blockade can trigger life-threatening bronchospasm)
Decompensated heart failure or cardiogenic shock
Sinus bradycardia (resting HR below 50 bpm) or second/third-degree heart block
Severe peripheral arterial disease or Raynaud's syndrome
Pheochromocytoma without prior alpha blockade (risk of hypertensive crisis from unopposed alpha stimulation)
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Propranolol Retatrutide
Status FDA Approved Extensively Studied
References 5 studies 6 studies
Latest 2023 2025-10
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.